Hepatitis C News and Research

Latest Hepatitis C News and Research

Viewpoints: Reps. on Medicare politics, policies, community pharmacies; Reflections on AIDS

The [Ryan] privatization proposal overlooks the fact that when it comes to rising health costs, Medicare is part of the solution, not the problem. ... Together with health care reform, Medicare can be the driver of innovation due to its sheer market share.

6 Jun 2011

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange, signed today an agreement to spin off its ophthalmic indications to a US based public company, Denali Concrete Management Inc.

6 Jun 2011

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech today announced the price of ROTAVAC India’s first indigenously developed Rotavirus Vaccine. The vaccine will be sold to global public markets, Governments worldwide including UN procurement agencies at a price of US $ 1.0. Bharat Biotech hopes its new vaccine will help prevent part of the ~ 500,000 child deaths each year caused due to rotavirus diarrhea and improve access to better, affordable rotavirus vaccines.

6 Jun 2011

GAVI welcomes lower pentavalent vaccine price

In the lead up to its first pledging conference on June 13, the GAVI Alliance announced today it has achieved commitments from two emerging market vaccine manufacturers to lower prices for the life-saving pentavalent vaccine, which protects against five deadly diseases. Developed country manufacturers have also offered price reductions on rotavirus and human papillomavirus, or HPV, vaccines.

5 Jun 2011

Primary care providers treat hepatitis C patients effectively through Project ECHO model

Under a completely new way of providing health care, primary care clinicians in remote villages, prisons and poor urban neighborhoods who were trained to treat patients with hepatitis C achieved excellent results identical to those of specialists at a university medical center.

4 Jun 2011

UCLA pediatric investigators earn top accolades at TTCF Faculty Presentation Awards

A new therapy for type 1 diabetes? A promising treatment for deadly viruses? Does a common treatment for children with severe infection actually cause more harm than good? These are important questions being investigated by pediatric researchers at Mattel Children's Hospital UCLA.

4 Jun 2011

Technology, expert training and real-time feedback improves Hepatitis C outcomes

Widely-available technology, expert training and real-time feedback helped ensure that patients treated for Hepatitis C in local communities did as well as patients treated at a university-based medical center, results of a new study funded by HHS' Agency for Healthcare Research and Quality show. The study is published in the June 2 online issue of the New England Journal of Medicine and in the June 9 print edition.

3 Jun 2011

AHF to host 'Remember AIDS' event on June 5

Hundreds of community members are expected to join AIDS Healthcare Foundation (AHF) at a candlelight vigil and march to mark the 30th anniversary of the discovery of HIV. The "Remember AIDS" event—which will take place on Sunday, June 5th—will begin with a gathering at Matthew Shepard Memorial Park at 7:00 pm.

3 Jun 2011

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

The first study of the social and ethical issues associated with a provocative approach to treatment for ulcerative colitis has found that the majority of potential patients are eager for what is now called "fecal microbiota transplantation" to become available, although many have concerns about donor selection, screening, and methods of delivery.

3 Jun 2011

Elastography and serum markers show promise in patients with liver disease

Patients who are evaluated for liver diseases such as hepatitis C (HCV) are typically recommended for liver biopsy to determine the extent of disease progression.

3 Jun 2011

Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis

Patients who are evaluated for liver diseases such as hepatitis C (HCV) are typically recommended for liver biopsy to determine the extent of disease progression. For patients who question whether less invasive testing is available, clinicians now have alternatives options to consider. Elastography and serum markers are two such diagnostic options reviewed in an editorial published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

2 Jun 2011

Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C

Anadys Pharmaceuticals, Inc. today announced issuance of the U.S. patent covering setrobuvir, the Company's Direct-Acting Antiviral in Phase IIb development for chronic hepatitis C virus infection.

2 Jun 2011

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

On May 29, 2011 XTL has announced that its rHuEPO drug which is currently in preparations for phase 2 clinical trial, has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer.

2 Jun 2011

Some Veterans' health jeopardized due to poor infection control

Herman Williams came home safely after fighting in the jungles of Vietnam as a Marine. He was shocked to learn four decades later that his military service had again placed him in jeopardy — this time, because he got a tooth pulled. Williams is among 13,000 U.S. veterans who have been warned in the last two years that their blood should be tested for potentially fatal infections after possible exposures by improper hygiene practices at five VA hospitals in Ohio, Florida, Georgia, Missouri and Tennessee.

31 May 2011

Two new hepatitis C drugs effectively improve cure rates of African Americans

Two new drugs just approved by the Food and Drug Administration to treat hepatitis C genotype 1 significantly improved the cure rates of patients. One of the drugs was extremely effective in treating African Americans.

27 May 2011

Pharmasset, Bristol-Myers Squibb initiate PSI-7977 plus BMS-790052 combination Phase 2a trial in HCV

Pharmasset, Inc. announced today the initiation of a Phase 2a trial investigating the combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and BMS-790052, Bristol-Myers Squibb Company's NS5A replication complex inhibitor, for the treatment of chronic hepatitis C.

26 May 2011

PBS' NewHour examines health insurance for 'urban poor' in Pakistan

PBS' NewsHour special correspondent Saima Mohsin on Monday reported from Pakistan on "an innovative health insurance plan for the urban poor." In Pakistan, 99 percent of the country's low-income population does not have health insurance, and this plan, called Naya Jeevan, "hopes to change that.

26 May 2011

Scarcity of resources calls for equitable distribution system for novel HCV treatment

For many patients with the hepatitis C virus, direct antiviral agents (DAA) offer a potential cure for the disease. The Food and Drug Administration (FDA) has recently approved two new DAAs, telaprevir and boceprevir, and with that clinicians must now decide who should be the first to receive this treatment.

25 May 2011

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Apollo centre for liver disease and transplantation has completed 100 liver transplantations in less than 4 years with over 90% success rate, creating a milestone in the history of medicine.

25 May 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Viewpoints: Reps. on Medicare politics, policies, community pharmacies; Reflections on AIDS

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Bharat Biotech announces the pricing for ROTAVAC vaccine

GAVI welcomes lower pentavalent vaccine price

Primary care providers treat hepatitis C patients effectively through Project ECHO model

UCLA pediatric investigators earn top accolades at TTCF Faculty Presentation Awards

Technology, expert training and real-time feedback improves Hepatitis C outcomes

AHF to host 'Remember AIDS' event on June 5

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

Elastography and serum markers show promise in patients with liver disease

Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis

Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

Some Veterans' health jeopardized due to poor infection control

Two new hepatitis C drugs effectively improve cure rates of African Americans

Pharmasset, Bristol-Myers Squibb initiate PSI-7977 plus BMS-790052 combination Phase 2a trial in HCV

PBS' NewHour examines health insurance for 'urban poor' in Pakistan

Scarcity of resources calls for equitable distribution system for novel HCV treatment

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in